Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
Bio-Techne (NASDAQ: TECH) expanded its collaboration with Oxford Nanopore Technologies and broadened commercial rights to develop a portfolio of genetics products on Oxford Nanopore platforms.
The agreement formally extends the partnership through 2032, builds on the March 2025 launch of the AmplideX Nanopore Carrier Plus Kit, and establishes a framework to define and propose future targeted enrichment sequencing kits for screening and diagnosis of heritable genetic disorders.
The companies said the enhancement will streamline coordination on development and commercialization and support Bio-Techne's diagnostics growth strategy by accelerating innovation and portfolio planning.
Bio-Techne (NASDAQ: TECH) ha ampliato la sua collaborazione con Oxford Nanopore Technologies e ha esteso i diritti commerciali per sviluppare un portafoglio di prodotti genetici sulle piattaforme Oxford Nanopore.
L'accordo estende formalmente la partnership fino al 2032, si basa sul lancio di marzo 2025 del AmplideX Nanopore Carrier Plus Kit, e crea un quadro per definire e proporre futuri kit di arricchimento mirato per lo screening e la diagnostica di disturbi genetici ereditari.
Le aziende hanno detto che l'ampliamento migliorerà la coordinazione nello sviluppo e nella commercializzazione e sosterrà la strategia di crescita diagnostics di Bio-Techne accelerando l'innovazione e la pianificazione del portfolio.
Bio-Techne (NASDAQ: TECH) amplió su colaboración con Oxford Nanopore Technologies y expandió los derechos comerciales para desarrollar una cartera de productos genéticos en las plataformas de Oxford Nanopore.
El acuerdo extiende formalmente la asociación hasta 2032, se apoya en el lanzamiento de marzo de 2025 del AmplideX Nanopore Carrier Plus Kit, y establece un marco para definir y proponer futuros kits de enriquecimiento dirigido para el cribado y diagnóstico de trastornos genéticos heredables.
Las empresas dijeron que la mejora facilitará la coordinación en el desarrollo y la comercialización y apoyará la estrategia de crecimiento de diagnósticos de Bio-Techne acelerando la innovación y la planificación de su cartera.
Bio-Techne (NASDAQ: TECH)는 Oxford Nanopore Technologies와의 협력을 확대하고 Oxford Nanopore 플랫폼에서 유전학 제품 포트폴리오를 개발하기 위한 상업적 권한을 확대했습니다.
계약은 파트너십을 2032년까지 확장한다고 공식적으로 밝히고 있으며, 2025년 3월 출시된 AmplideX Nanopore Carrier Plus Kit를 기반으로 하며, 유전 질환의 선별 및 진단을 위한 표적 증강 시퀀싱 키트를 정의하고 제안하기 위한 프레임워크를 마련합니다.
두 회사는 이 개선이 개발 및 상용화에 대한 조정 능력을 간소화하고, Bio-Techne의 진단 성장 전략을 가속화하여 혁신 및 포트폴리오 기획을 지원할 것이라고 밝혔습니다.
Bio-Techne (NASDAQ: TECH) a élargi sa collaboration avec Oxford Nanopore Technologies et élargi les droits commerciaux pour développer un portefeuille de produits génétiques sur les plateformes Oxford Nanopore.
L'accord prolonge formellement le partenariat jusqu'en 2032, s'appuie sur le lancement de mars 2025 du AmplideX Nanopore Carrier Plus Kit, et établit un cadre pour définir et proposer de futurs kits d'enrichissement ciblé pour le dépistage et le diagnostic des troubles génétiques héréditaires.
Les entreprises ont déclaré que cette amélioration facilitera la coordination du développement et de la commercialisation et soutiendra la stratégie de croissance des diagnostics de Bio-Techne en accélérant l'innovation et la planification du portefeuille.
Bio-Techne (NASDAQ: TECH) hat seine Zusammenarbeit mit Oxford Nanopore Technologies erweitert und die kommerziellen Rechte zur Entwicklung eines Portfolios genetischer Produkte auf den Plattformen von Oxford Nanopore erweitert.
Die Vereinbarung verlängert die Partnerschaft formell bis 2032, baut auf die im März 2025 eingeführte AmplideX Nanopore Carrier Plus Kit auf und schafft einen Rahmen, um zukünftige zielgerichtete Enrichment-Sequencing-Kits für das Screenen und die Diagnose vererbter genetischer Störungen zu definieren und vorzuschlagen.
Die Unternehmen sagten, die Erweiterung werde die Koordination bei Entwicklung und Vermarktung straffen und Bio-Technes Diagnostics-Wachstumsstrategie durch Beschleunigung von Innovation und Portfolioplanung unterstützen.
Bio-Techne (NASDAQ: TECH) وسّعت تعاونها مع شركة Oxford Nanopore Technologies ووسّعت حقوقها التجارية لتطوير محفظة من منتجات الوراثة على منصات Oxford Nanopore.
الاتفاق يوسّع الشراكة رسميًا حتى 2032، ويعتمد على إطلاق مارس 2025 لـ AmplideX Nanopore Carrier Plus Kit، ويؤسس إطارًا لتعريف واقتراح مجموعات مستقبلية من كتَل التّركيز المستهدَف للتمشيط والتشخيص لمشكلات وراثية قابلة للوراثة.
وقالت الشركات إن هذا التطوير سيُسهم في تبسيط التنسيق في التطوير والتسويق ويدعم استراتيجيةBio-Techne لنمو التشخيصات من خلال تسريع الابتكار وتخطيط المحفظة.
Bio-Techne (NASDAQ: TECH) 扩大了与 Oxford Nanopore Technologies 的合作，并拓宽在 Oxford Nanopore 平台上开发基因产品组合的商业权利。
该协议正式 将伙伴关系扩展至 2032 年，并以 2025 年 3 月推出的 AmplideX Nanopore Carrier Plus Kit 为基础，建立一个框架，用于定义和提出未来用于筛查和诊断遗传性疾病的定向富集测序试剂盒。
双方表示，此次增强将简化研发与商业化的协调，并通过加速创新和产品组合规划来支持 Bio-Techne 的诊断增长战略。
- Collaboration extended through 2032
- Expanded commercial rights to develop a genetics product portfolio
- Framework established to propose future targeted enrichment sequencing kits
- None.
Insights
Expanded collaboration with Oxford Nanopore extends commercialization rights and partnership through
Bio‑Techne gains broader commercial rights to develop targeted enrichment sequencing kits on Oxford Nanopore platforms, building on the AmplideX® Nanopore Carrier Plus Kit launched in
Key dependencies include successful development, regulatory clearance where required, and effective commercialization execution with Oxford Nanopore. The extension to
Watch for new kit announcements, regulatory filings, and adoption metrics over the next 12–36 months; those milestones will show whether the agreement translates into measurable diagnostics revenue and broader market penetration.
- Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit
- Establishes a framework to define and propose future portfolios
- Extends collaboration through 2032, reinforcing Bio-Techne's diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies
Building upon the successful launch of the AmplideX® Nanopore Carrier Plus Kit in March 2025, the enhanced collaboration streamlines coordination on the development and commercialization of a broader portfolio of targeted enrichment sequencing kits for the screening and diagnosis of heritable genetic disorders.
"This expanded agreement underscores our commitment to advancing genetic testing solutions that simplify workflows and deliver richer insights for laboratories worldwide," said Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By deepening our collaboration with Oxford Nanopore, we are accelerating innovation in diagnostics and creating a foundation for future portfolios."
"We're pleased to expand our collaboration with Bio-Techne to bring new genetic testing solutions to laboratories worldwide. By combining Bio-Techne's diagnostics expertise and innovations with our advanced molecular sensing platform, together we can make testing faster, simpler, and more accessible," said Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, and YouTube.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies' vision is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Company has developed a new generation of nanopore-based sensing technology that is currently used for information-rich, rapid, accessible and affordable DNA and RNA analysis. The platform is also being developed for the analysis of proteins and metabolites. The technology is being used in more than 125 countries to understand the biology of humans, plants, animals, bacteria, viruses and environments, as well as a range of diseases including cancer.
Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: https://nanoporetech.com/
Contact:
Corporate Communications
media.relations@bio-techne.com
Investor Relations
David.clair@bio-techne.com
Oxford Nanopore
Media@nanoporetech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-oxford-nanopore-technologies-expand-agreement-to-accelerate-development-of-genetics-portfolio-through-2032-302579234.html
SOURCE Bio-Techne Corporation
FAQ
What did Bio-Techne announce about its deal with Oxford Nanopore on October 9, 2025 (TECH)?
How does the expanded agreement affect Bio-Techne's diagnostics strategy (TECH)?
Which product launch does the expanded agreement build upon for Bio-Techne (TECH)?
What product types will Bio-Techne and Oxford Nanopore coordinate under the extended deal (TECH)?
Will the agreement create a process for future product proposals between the companies (TECH)?
